Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — H1 2025 Earnings Presentation
20 slides from Hyphens Pharma International's earnings presentation, Aug 21, 2025
Slide 1: General Announcement: Results Briefing 1H2025
GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1H2025 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title General Announcement Date &Time of Broadcast 20-Aug-2025 20:0
Slide 2: Results Briefing 1H2025
RESULTS BRIEFING 1H2025 21 August 2025 HYPHENS PHARMA INTERNATIONAL LIMITED
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Agenda
Agenda 01 Business Updates 02 Financial Results 03 Business Outlook
Slide 5: Business Updates
oe g% Hyphens - a Business Updates
Slide 6: Business updates
Business updates Launch novel acne treatment Winlevi®, to Singapore and Malaysia Completion of the tranche 2 acquisition of Ardence Pharma Sdn Bhd. Obtained exclusive Acquired the Trademark of rights to commercialise Visiopro® in Singapore Metoject® in Singapore, Malaysia, the Philippines and Vietna
Slide 7: Financial Results
g% Hyphens Financial Results
Slide 8: Overall Performance
Overall Performance Revenue Gross Profit (SGDm) (SGDm) 34.8 34.7 35.3 99.6 33.9 95.9 95.8 89.5 28.0 74.7 1H2023 2H2023 1H2024 2H2024 1H2025 1H2023 2H2023 1H2024 2H2024 1H2025 GPM has improved from 34.9% during 1H2024 to 39.4% in 1H2025
Slide 9: Overall Performance
Overall Performance Profit after tax Operating Expenses (SGDm) (SGDm) Inventory Inventory provision provision S$2.1m 5.9 S$0.3m FX Loss 5.1 5.0 FX Loss S$0.8m S$2m Operating Operating Expenses Expenses 3.5 before FX before FX loss or loss or inventory inventory 2.0 provision provision S$26.5m S$28.5
Slide 10: So What Happened to Inventory?
So What Happened to Inventory? Distributor for Singapore business Principals Distributors for other geographical Contract markets manufacturers Statutory revenue In-market-sales recognition
Slide 11: Cash Generation from Operations
Cash Generation from Operations Cash Generated from Operations (SGDk) 7,269 483 1H2024 2H2024 1H2025 (423) During 1H2025, as a result, we managed to • release S$8.1m (-24%) of working capital from inventory • reduce bank borrowing by S$1.7m (-16%)
Slide 12: Performance by Geography
Performance by Geography Others, 11% Revenue by Geography SGDm Malaysia, 14% +2.5%, 47.0 Singapore Singapore, 52% 1H2025 45.9 -36.8%, 20.1 Vietnam, 22% Vietnam 31.8 -1.8%, 12.7 Others, 10% Malaysia 13.0 Malaysia, 13% +7.8%, 9.7 Singapore, 46% Others 9.0 1H2024 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 4
Slide 13: We have 3 Revenue Segments
We have 3 Revenue Segments 01 02 03 Specialty Specialty Pharmaceutical Proprietary Medical Hypermart Pharmaceuticals Principals Brands & Digital
Slide 14: Updating the name of our segments
Updating the name of our segments 01 02 03 Pharmaceutical Specialty & Proprietary Digital Platform & E- Medical Aesthetics Brands Pharmacy Pharmaceuticals
Slide 15: Revenue by Segment
Revenue by Segment Revenue by Segments • Pharmaceutical and Medical (SGDm) Aesthetics 120.0 • Transition of the brand Vivomixx® to Visiopro® • Fenosup® re-classified to 100.0 Proprietary Brands segment during 1H2025 21.7 21.9 22.0 • Reduction in sales in 80.0 20.4 Vietnam. 14.3 13.8 13.3 60.0 20.9 1
Slide 16: Segment Profitability
Segment Profitability EBITDA by Segment (SGDm) • Pharmaceutical and Medical 8.5 Aesthetics: • Suffered from one-off provision 6.9 of stock obsolesces for Sterimar of S$2m. 5.6 • Proprietary Brands 3.9 3.9 • Expansion of portfolio • Growth of Ceradan® and Ocean 2.5 2.6 2.6 Health® 1.4 1.4 • Digital P
Slide 17: Business Outlook
g% Hyphens Business Outlook
Slide 18: Business Outlook
Business Outlook Pharmaceutical and Digital Platform and Proprietary Brands Medical Aesthetics E-Pharmacy Resources behind the new launch of Grow medical aesthetics product Continue to pursue the platform Winlevi® in Singapore and Malaysia portfolio and expand geographically development, while furth
Slide 19: Q&A
Q&A
Slide 20: Let's improve lives together.
Let’s improve lives together. Hyphens Pharma International Limited (SGX: 1J5) hyphens-pharma-international Hyphen.com.sg 16 Tai Seng Street, Level 4, Singapore 534138
Hyphens Pharma International — H1 2025 Earnings Presentation on 6ix